Lab
Elite Bio Reference Laboratory LLC
Elite Bio Reference Laboratory LLC was paid $167K by Medicaid between Feb 2023 and Oct 2024, across 65 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 27% of everything it billed.
33Billing provider infoELITE BIO REFERENCE LABORATORY LLC
TAMPA, FL 33614
TAMPA, FL 33614
33aNPI1275292294assigned 12/17/2021
33bProvider typeClinical Medical Laboratory
28Total paid$167K
24GClaims28,424
24DCodes billed65
24AFirst – last monthFeb 2023 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#88 of 225
Median peer was paid$74K
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 9,136 | $26K | |
| 2024incomplete | 19,288 | $141K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 27% | 1,903 | 1,705 | $46K |
| 81238 | 6.9% | 103 | 99 | $12K | |
| 81223 | 5.3% | 48 | 46 | $9K | |
| 87481 | 5.1% | 1,887 | 1,697 | $8K | |
| 81286 | 4.8% | 203 | 199 | $8K | |
| 81419 | 4.0% | 75 | 75 | $7K | |
| 87507 | 3.6% | 94 | 94 | $6K | |
| 81345 | 3.6% | 145 | 142 | $6K | |
| 87631 | 2.9% | 1,361 | 1,304 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.7% | 1,930 | 1,742 | $5K |
| 87640 | 2.7% | 1,825 | 1,643 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.2% | 1,336 | 1,279 | $4K |
53 more codes
| 87653 | 2.1% | 1,782 | $4K | |
| 81185 | 1.9% | 69 | $3K | |
| 81321 | 1.8% | 40 | $3K | |
| 81175 | 1.8% | 28 | $3K | |
| 87634 | 1.8% | 1,349 | $3K | |
| 87500 | 1.5% | 804 | $3K | |
| 87556 | 1.3% | 1,238 | $2K | |
| 87498 | 1.2% | 1,340 | $2K | |
| 87581 | 1.2% | 1,345 | $2K | |
| 87541 | 1.2% | 1,345 | $2K | |
| 87486 | 1.2% | 1,345 | $2K | |
| 87532 | 1.2% | 1,238 | $2K | |
| 87496 | 1.2% | 1,238 | $2K | |
| 87150 | <1% | 322 | $2K | |
| 86413 | <1% | 1,164 | $2K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 60 | $1K |
| 87503 | <1% | 1,336 | $1K | |
| 81236 | <1% | 29 | $1K | |
| 87641 | <1% | 403 | $1K | |
| 81302 | <1% | 110 | $1K | |
| 81309 | <1% | 67 | $1K | |
| 81189 | <1% | 65 | $756.32 | |
| 87551 | <1% | 38 | $591.60 | |
| 81192 | <1% | 40 | $570.51 | |
| 81191 | <1% | 40 | $570.51 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 38 | $419.76 |
| 81312 | <1% | 39 | $377.02 | |
| 81329 | <1% | 27 | $377.02 | |
| 81171 | <1% | 28 | $377.02 | |
| 81271 | <1% | 40 | $377.02 | |
| 81508 | <1% | 16 | $224.73 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 23 | $205.24 |
| 81256 | <1% | 54 | $183.70 | |
| 81260 | <1% | 40 | $108.17 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 42 | $0.00 |
| 81243 | 0% | 16 | $0.00 | |
| 81333 | 0% | 15 | $0.00 | |
| 81275 | 0% | 14 | $0.00 | |
| 81434 | 0% | 16 | $0.00 | |
| 81311 | 0% | 14 | $0.00 | |
| 81325 | 0% | 15 | $0.00 | |
| 81330 | 0% | 45 | $0.00 | |
| 81181 | 0% | 16 | $0.00 | |
| 81255 | 0% | 16 | $0.00 | |
| 81351 | 0% | 14 | $0.00 | |
| 81320 | 0% | 14 | $0.00 | |
| 81254 | 0% | 16 | $0.00 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 15 | $0.00 |
| 81430 | 0% | 16 | $0.00 | |
| 81251 | 0% | 16 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 42 | $0.00 |
| 81200 | 0% | 16 | $0.00 | |
| 82387 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARPER, CHAD (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Elite Clinical Laboratory, INC | Houston, TX | $367K |
| Redwood Lab Services, LLC | Houston, TX | $75K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.